In vitro studies show that using CCL5-neutralizing antibodies can abolish the resistance of AML cells with FLT3 mutations to FLT3 tyrosine kinase inhibitors, suggesting CCR5 or its ligands as convenient therapeutic targets. This evidence concerns the gene FLT3 and acute myeloid leukemia.